Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance

Current Opinion in Lipidology

Volumn 21, Issue 4, 2010, Pages 329-336

  Savage, David B ^a   Semple, Robert K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

diabetes; dyslipidaemia; fatty liver; hepatic steatosis; insulin receptor; insulin resistance; VLDL

Indexed keywords

CCAAT BINDING FACTOR; FATTY ACID; INSULIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; X BOX BINDING PROTEIN 1;

DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; FAT INTAKE; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; LIPOGENESIS; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; COMPLICATION; ENDOPLASMIC RETICULUM; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; DYSLIPIDEMIAS; ENDOPLASMIC RETICULUM; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM;

EID: 77954956697     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833b7782     Document Type: Review

References (52)

1. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91:4753-4761.
2. Bellentani S, Saccoccio G, Masutti F, etal. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112-117.
3. Bonora E, Kiechl S, Willeit J, etal. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004; 53:1782-1789.
4. Brown CD, Higgins M, Donato KA, etal. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8:605-619.
5. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925-929.
6. De Silva NM, Frayling TM. Novel biological insights emerging from genetic studies of type 2 diabetes and related metabolic traits. Curr Opin Lipidol 2010; 21:44-50.
7. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008; 34 (6 Pt 2):634-637.
8. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30:162-172.
9. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292:2495-2499.
10. Gibbons GF. A comparison of in-vitro models to study hepatic lipid and lipoprotein metabolism. Curr Opin Lipidol 1994; 5:191-199.
11. Boess F, Kamber M, Romer S, etal. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003; 73:386-402.
12. Hart SN, Li Y, Nakamoto K, et al. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 2010; 38:988-994.
13. Chakravarthy MV, PanZ, Zhu Y, etal. New' hepatic fat activates PPARalphato maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 2005; 1:309-322.
14. Donnelly KL, Smith CI, Schwarzenberg SJ, etal. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
15. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (Suppl 3):14-23.
16. Karagianni C, Stabouli S, Roumeliotou K, etal. Severe hypertriglyceridaemia in diabetic ketoacidosis: clinical and genetic study. Diabet Med 2004; 21:380-382. (Pubitemid 38519676)
17. Bickerton AS, Roberts R, Fielding BA, et al. Adipose tissue fatty acid metabolism in insulin-resistant men. Diabetologia 2008; 51:1466-1474.
18. Holt HB, Wild SH, Wood PJ, etal. Nonesterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006; 49:141-148.
19. Semple RK, Sleigh A, Murgatroyd PR, etal. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119:315-322.
20. Ravikumar B, Carey PE, Snaar JE, etal. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. Am J Physiol Endocrinol Metab 2005; 288:E789-797.
21. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135:2503-2506.
22. Erion DM, Ignatova ID, Yonemitsu S, etal. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab 2009; 10:499-506.
23. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008; 8:359-371.
24. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51:1584-1592.
25. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 2008; 8:212-223.
26. Gibbons GF, Wiggins D, Brown AM, et al. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 2004; 32 (Pt 1):59-64.
27. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277:17377-17380.
28. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118: 2347-2364.
29. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7:125-134.
30. Han S, Liang CP, Westerterp M, et al. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest 2009; 119:1029-1041.
31. Christ ER, Carroll PV, Albany E, et al. Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2001; 55:777-787.
32. Markmann JF, Rosen M, Siegelman ES, et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003; 52:1591-1594.
33. Lee Y, Ravazzola M, Park BH, et al. Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. Diabetes 2007; 56:2295-2301.
34. Sumiyoshi S, Kobayashi Y, Souda K, et al. Images of interest. Hepatobiliary and pancreatic: insulinoma metastases with focal hepatic steatosis. J Gastroenterol Hepatol 2005; 20:650.
35. Meyer L, Jeantroux J, Riveline JP, et al. Reversible focal hepatic steatosis in type 1 diabetic patients treated with intraperitoneal insulin implantable pump therapy. Diabetes Care 2008; 31:e49.
36. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007; 104:12587-12594.
37. Shimomura I, Matsuda M, Hammer RE, et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipody-strophic and ob/ob mice. Mol Cell 2000; 6:77-86.
38. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7:85-96.
39. Taniguchi CM, Kondo T, Sajan M, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 2006; 3:343-353.
40. Sajan MP, Standaert ML, Nimal S, et al. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity. J Lipid Res 2009; 50:1133-1145.
41. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107:3441-3446.
42. Dong XC, Copps KD, Guo S, et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008; 8:65-76.
43. SopasakisVR, Liu P, Suzuki R, etal. Specific roles of the p110 alphais of ormof phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab 2010; 11:220-230.
44. Leavens KF, Easton RM, Shulman GI, et al. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 2009; 10:405-418.
45. Hoehn KL, Hohnen-Behrens C, Cederberg A, etal. IRS1-independent defects define major nodes of insulin resistance. Cell Metab 2008; 7:421-433.
46. Ozcan U, Cao Q, Yilmaz E, etal. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306:457-461.
47. Oyadomari S, Harding HP, Zhang Y, et al. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatos-teatosis in mice. Cell Metab 2008; 7:520-532.
48. OtaT, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 2008; 118:316-332.
49. Lee AH, Scapa EF, Cohen DE, etal. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 2008; 320:1492-1496.
50. ParkSW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat Med 2010; 16:429-437.
51. Winnay JN, Boucher J, Mori MA, etal. A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med 2010; 16:438-445.
52. Kammoun HL, Chabanon H, Hainault I, etal. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009; 119:1201-1215.